查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1212621

膀胱过动症(OAB)治疗药的全球市场 2023

Overactive Bladder (OAB) Therapeutics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 271 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

膀胱过动症(OAB)治疗药的全球市场到2030年将达到15亿美元

在COVID-19后改变的商务环境中，2022年12亿美元的膀胱过动症(OAB)治疗药的全球市场到2030年将达到15亿美元的规模，在分析期间2022年～2030年间预计将以2.8％的年复合成长率增长。本报告所分析的市场区隔之一的抗胆碱药，年复合成长率将记录3.1％，到分析期间结束时达到6亿1470万美元。考虑疫情后的復苏，神经刺激领域今后8年的年复合成长率将修正为2.4％。

美国市场估算为3亿2,490万美元，中国则将以年复合成长率4.8％的速度成长。

美国的膀胱过动症(OAB)治疗药市场在2022年估算为3亿2,490万美元。作为世界第2大经济大国的中国，在2022年～2030年间年复合成长率预计将为4.8％，2030年市场规模达到2亿9070万美元。其他热门的地区市场有日本和加拿大，在2022年～2030年间预计将各以1.5％和2.4％的速度成长。在欧洲市场中，德国将以年复合成长率1.9％成长。亚太地区的市场，澳洲，印度，韩国等国家推动下，2030年达到1亿9,090万美元。

调查对像企业范例

  • Allergan PLC
  • Astellas Pharma, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo Pharmaceuticals, Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Recordati SpA
  • Speciality European Pharma Ltd.
  • Sunovion Pharmaceuticals, Inc.

目录

第1章 调查手法

第2章 摘要整理

  • 市场概要
  • 主要企业
  • 市场趋势与推动因素
  • 全球市场预测

第3章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美国家
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 其他中东
  • 非洲

第4章 竞争

简介目录
Product Code: MCP-6499

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Overactive Bladder (OAB) Therapeutics Market to Reach $1.5 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Overactive Bladder (OAB) Therapeutics estimated at US$1.2 Billion in the year 2022, is projected to reach a revised size of US$1.5 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2022-2030. Anticholinergics, one of the segments analyzed in the report, is projected to record a 3.1% CAGR and reach US$614.7 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Neurostimulation segment is readjusted to a revised 2.4% CAGR for the next 8-year period.

The U.S. Market is Estimated at $324.9 Million, While China is Forecast to Grow at 4.8% CAGR

The Overactive Bladder (OAB) Therapeutics market in the U.S. is estimated at US$324.9 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$290.7 Million by the year 2030 trailing a CAGR of 4.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.5% and 2.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$190.9 Million by the year 2030.

Select Competitors (Total 34 Featured):

  • Allergan PLC
  • Astellas Pharma, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo Pharmaceuticals, Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Recordati SpA
  • Speciality European Pharma Ltd.
  • Sunovion Pharmaceuticals, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Overactive Bladder (OAB) Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 3: World 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 6: World 18-Year Perspective for Anticholinergics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Neurostimulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Neurostimulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 9: World 18-Year Perspective for Neurostimulation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Botox by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Botox by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 12: World 18-Year Perspective for Botox by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Mirabegron by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Mirabegron by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 15: World 18-Year Perspective for Mirabegron by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 16: World Overactive Bladder (OAB) Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2012 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 19: USA 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 22: Canada 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • JAPAN
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 25: Japan 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • CHINA
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 28: China 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • EUROPE
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 31: Europe 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 34: Europe 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • FRANCE
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 37: France 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • GERMANY
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 40: Germany 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 43: Italy 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • UNITED KINGDOM
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 46: UK 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • SPAIN
    • TABLE 47: Spain Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Spain Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 49: Spain 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • RUSSIA
    • TABLE 50: Russia Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Russia Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 52: Russia 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 55: Rest of Europe 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • ASIA-PACIFIC
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 58: Asia-Pacific 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 61: Asia-Pacific 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • AUSTRALIA
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 62: Australia Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Australia Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 64: Australia 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • INDIA
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 65: India Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 66: India Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 67: India 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • SOUTH KOREA
    • TABLE 68: South Korea Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 69: South Korea Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 70: South Korea 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Rest of Asia-Pacific Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 73: Rest of Asia-Pacific 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • LATIN AMERICA
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 76: Latin America 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2023 & 2030
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 79: Latin America 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • ARGENTINA
    • TABLE 80: Argentina Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Argentina Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 82: Argentina 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • BRAZIL
    • TABLE 83: Brazil Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Brazil Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 85: Brazil 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • MEXICO
    • TABLE 86: Mexico Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Mexico Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 88: Mexico 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Rest of Latin America Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 91: Rest of Latin America 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • MIDDLE EAST
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 94: Middle East 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2023 & 2030
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 97: Middle East 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • IRAN
    • TABLE 98: Iran Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Iran Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 100: Iran 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • ISRAEL
    • TABLE 101: Israel Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Israel Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 103: Israel 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Saudi Arabia Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 106: Saudi Arabia 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 107: UAE Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 108: UAE Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 109: UAE 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Rest of Middle East Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 112: Rest of Middle East 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030
  • AFRICA
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 113: Africa Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 114: Africa Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
    • TABLE 115: Africa 18-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2012, 2023 & 2030

IV. COMPETITION